Antiviral Treatment on Pregnancy with COVID-19 Infection : A Systematic Review
Abstract
Objective to evaluate antiviral treatment, duration, and side effects on pregnant women based on gestational age and severity of COVID-19 infection. Method: a systematic review of antiviral treatment, duration, and side effects on pregnant women based on gestational age and severity of COVID-19 infection. Systematic review was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement. Result 948 papers accessed through Pubmed, Scopus, Science Direct, Cohcrane, and other with keywords “Antiviral”, “Pregnancy” “Pregnant” “Coronavirus” “COVID-19” “SARS-CoV-2”. Duplicate papers were excluded (n=302), topics and abstracts that do not meet the criteria (n=612), and 25 papers that did not meet the inclusion criteria. 9 papers that meet the inclusion criteria (case reports and cohort retrospective case study) discussed 20 pregnant women with COVID-19 infection (16 moderate and severe cases received Remdesivir, 3 moderate and mild cases received Lopinavir-ritonavir combination, and 1 moderate case received Arbidol). Conclusion, remdesivir is an antiviral frequently used in pregnancy on trimester II and III with severe COVID-19 infection with a duration of treatment of 5-10 days. Remdesivir should be monitored because some show side effects of increasing liver function.
Pengobatan Ibu Hamil yang Terinfeksi COVID−19 dengan Antivirus
Abstrak
Tujuan untuk mengevaluasi penggunaan obat antivirus, lama pengobatan, dan efek samping pada wanita hamil dengan infeksi COVID-19 berdasarkan usia kehamilan dan derajat keparahan. Metode tinjauan literatur sistematis tentang penggunaan obat antivirus, lama pengobatan, dan efek samping pada wanita hamil dengan infeksi COVID-19 berdasarkan usia kehamilan dan tingkat keparahan. Tinjauan sistematis mengikuti pedoman dari Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Hasil terdapat 948 jurnal yang diakses melalui Pubmed, Scopus, Science Direct, Cohcrane dan lainya dengan kata kunci : Antiviral, Pregnancy, Pregnant, Coronavirus, COVID-19, SARS-CoV-2. Terdapat jurnal yang terduplikasi (n=302), topik dan abstrak yang tidak sesuai kriteria (n=612), dan 25 jurnal yang tidak sesuai kriteria inklusi. Terdapat 9 jurnal yang memenuhi kriteria inklusi (laporan kasus dan studi retrosepktif kohort) yang membahas 20 wanita hamil dengan infeksi COVID-19 (16 kasus dengan derajat sedang dan berat menerima Remdesivir, 3 kasus derajat sedang dan ringan menerima kombinasi Lopinavir-ritonavir, dan 1 kasus derajat sedang menerima Arbidol). Kesimpulan, remdesivir adalah antivirus yang sering digunakan pada wanita hamil trisemester II dan III dengan infeksi COVID-19 derajat berat, lama pengobatan 5-10 hari. Remdesivir harus diwaspadai karena dapat menimbulkan efek samping seperti peningkatan fungsi hati.
Kata kunci: Antivirus, Hamil, COVID-19
Keywords
Full Text:
PDFReferences
Li L, Wang X, Wang R, Hu Y, Jiang S, Lu X. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Design, Development and Therapy. 2020;Volume 14:3001-3013. (1)
Cavalcante M, Cavalcante C, Braga A, Andrade D, Montenegro M, Santos P et al. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe und Frauenheilkunde. 2021;81(01):46-60.
Wu D, Fang D, Wang R, Deng D, Liao S. Management of Pregnancy during the COVID‐19 Pandemic. Global Challenges. 2020;5(2):2000052.
Anderson J, Schauer J, Bryant S, Graves CR. The use of CONVALESCENT plasma therapy and remdesivir in the successful management of a critically ILL obstetric patient with novel Coronavirus 2019 Infection: A case report. Case Reports in Women's Health. 2020;27.
Akpinar G, Tastan C. The Overall Consequence of Antiviral Drugs Given to Pregnant Women with COVID-19. J Bacteriolv Parasitol. 2021. S10: 002.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 STATEMENT: An UPDATED guideline for reporting systematic reviews. BMJ. 2021;
Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine. 2018;23(2):60–3.
Halscott T and Vaught J. Management considerations for pregnant patients with COVID-19. Society of Maternal and Fetal Medicine, 2020
Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick R. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). Obstetrics & Gynecology. 2020;136(5):1025-1029.
McCoy J, Short W, Srinivas S, Levine L, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. American Journal of Obstetrics & Gynecology MFM. 2020;2(3):100164.
Igbinosa I, Miller S, Bianco K, Nelson J, Kappagoda S, Blackburn B et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. American Journal of Obstetrics and Gynecology. 2020;223(5):768-770.
Dande R, Qureshi A, Persaud K, Puri C, Zulfiqar S, Awasthi S. Remdesivir in a pregnant patient with COVID-19 pneumonia. Journal of Community Hospital Internal Medicine Perspectives. 2021;11(1):103-106.
Saroyo Y, Rumondang A, Febriana I, Harzif A, Irwinda R. Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report. Infectious Disease Reports. 2021;13(2):437-443.
Maldarelli G, Savage M, Mazur S, Oxford-Horrey C, Salvatore M, Marks K. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. Open Forum Infectious Diseases. 2020;7(9)
Jacobson J, Antony K, Beninati M, Alward W, Hoppe K. Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. Case Reports in Women's Health. 2021;29:e00273.
Ogamba I, Chuang L, Panarelli E, Zilberman D. A case report of COVID-19 infection and management during pregnancy. SAGE Open Medical Case Reports. 2021;9:2050313X2110158.
Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm Delivery. Clinical Infectious Diseases. 2020;71(15):844-846.
Castro P, Matos A, Werner H, Lopes F, Tonni G, Araujo Júnior E. Covid-19 and Pregnancy: An Overview. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics. 2020;42(07):420-426.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule gs-5734 against ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–5.)
Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine. 2019;381(24):2293–303)
Assessment report - European Medicines Agency [Internet]. [cited 2021Sep12]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/veklury-epar-public-assessment-report_en.pdf
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—The Science of Safety and Effectiveness)
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe covid-19. New England Journal of Medicine. 2020;382(24):2327–36.)
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — final report. New England Journal of Medicine. 2020;383(19):1813–26.)
Bertolini A, Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, et al. Abnormal liver function tests in patients with covid‐19 : Relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–72).
Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital With Covid-19 (RECOVERY): A RANDOMISED, CONTROLLED, OPEN-LABEL, Platform trial. The Lancet. 2020;396(10259):1345–52.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. New England Journal of Medicine. 2020;382(19):1787–99.
(Kim A and Gandhi R. Coronavirus disease 2019 (COVID-19): management in hospitalized adults. Waltham, MA: Uptodate, 2020.)
(Taylor M, Kobeissi L, Kim C, Amin A, Thorson A, Bellare N et al. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. The Lancet Global Health. 2021;9(3):e366-e371.)
(Mei Y, Luo D, Wei S, Liao X, Pan Y, Yang X et al. Obstetric Management of COVID-19 in Pregnant Women. Frontiers in Microbiology. 2020;11.).
Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of Arbidol (Umifenovir) on covid-19: A randomized controlled trial. BMC Infectious Diseases. 2020;20(1).
Lu D, Sang L, Du S, Li T, Chang Y, Yang XA. Asymptomatic COVID‐19 infection in late pregnancy indicated no vertical transmission. Journal of Medical Virology. 2020;92(9):1660–4.
DOI: http://dx.doi.org/10.24198/obgynia.v4i2s.329
Refbacks
- There are currently no refbacks.
_CROSREF22.jpg)
